FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
Yannan JiaWeiguo ZhangMahesh BasyalKyung Hee ChangLauren B OstermannJared K BurksCharlie LyHong Mu-MosleyQi ZhangXin HanWilliam E FoglerJohn L MagnaniArnaud LesegretainAnna A ZalTomasz ZalMichael AndreeffPublished in: Leukemia (2023)